Pathophysiogical and therapeutic progress in Friedreich ataxia

Area of Science:

• Genetics and Molecular Biology
• Neuroscience
• Cardiology

Background:

• Friedreich ataxia (FRDA) is the most common hereditary autosomal recessive ataxia.
• It is a multisystemic condition often involving cardiomyopathy and diabetes.
• FRDA results from GAA-triplet repeat expansion in the FXN gene, reducing frataxin levels.

Purpose of the Study:

• To review the pathophysiological consequences of FXN mutations in FRDA.
• To evaluate current animal and cellular models for FRDA research.
• To outline therapeutic strategies for FRDA, focusing on restoring frataxin levels.

Main Methods:

• Review of existing literature on FRDA pathogenesis and models.
• Analysis of data from animal models (conditional knockout, knock-in, transgenic).
• Examination of patient-derived cellular models, including induced pluripotent stem cell (iPSC)-derived neurons and cardiomyocytes.

Main Results:

• Animal models partially recapitulate FRDA features but often lack genetic context or show mild phenotypes.
• Patient-derived iPSC neurons show maturation delays and reduced mitochondrial potential.
• FRDA cardiomyocytes exhibit mitochondrial degeneration and altered mitochondrial dynamics.

Conclusions:

• Patient-derived cells are the most relevant models for studying frataxin deficiency.
• Targeting the GAA repeat expansion with histone deacetylase inhibitors (HDACi) is a promising therapeutic strategy.
• Restoring frataxin levels is a key goal for FRDA treatment development.